These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9140134)

  • 1. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
    Gassen M; Youdim MB
    Pharmacol Toxicol; 1997 Apr; 80(4):159-66. PubMed ID: 9140134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron and Parkinson's disease: chelators to the rescue?
    Levenson CW
    Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
    Weinreb O; Mandel S; Youdim MBH; Amit T
    Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
    Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
    Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress and neurodegeneration: the involvement of iron.
    Carocci A; Catalano A; Sinicropi MS; Genchi G
    Biometals; 2018 Oct; 31(5):715-735. PubMed ID: 30014355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
    Kaur D; Andersen JK
    Aging Cell; 2002 Oct; 1(1):17-21. PubMed ID: 12882349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
    Jenner P
    Pathol Biol (Paris); 1996 Jan; 44(1):57-64. PubMed ID: 8734302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
    Apostolakis S; Kypraiou AM
    Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
    Jellinger KA
    Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron and Parkinson's disease.
    Di Lorenzo F
    Neuro Endocrinol Lett; 2015; 36(1):24-7. PubMed ID: 25789591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
    Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
    Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free-radical toxicity and antioxidant medications in Parkinson's disease.
    Ciccone CD
    Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
    [No Abstract]   [Full Text] [Related]  

  • 20. An introduction to the free radical hypothesis in Parkinson's disease.
    Olanow CW
    Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.